First Light Asset Management »

Enliven Therapeutics shares owned by First Light Asset Management

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by First Light Asset Management from 13F filings

Historical chart of First Light Asset Management investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by First Light Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by First Light Asset Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $7.9M 202k 39.20

More positions owned by First Light Asset Management

Axogen Common Stocks (AXGN)
Palvella Therapeutics Common Stocks (PVLA)
Neogenomics Common Stocks (NEO)
Si-bone Common Stocks (SIBN)
Centessa Pharmaceuticals Common Stocks (CNTA)
Apogee Therapeutics Common Stocks (APGE)
Amylyx Pharmaceuticals Common Stocks (AMLX)
Twist Bioscience Corporation Common Stocks (TWST)
Crinetics Pharmaceuticals Common Stocks (CRNX)
908 Devices Common Stocks (MASS)
Neuropace Common Stocks (NPCE)
Edgewise Therapeutics Common Stocks (EWTX)
Anaptys Bio Common Stocks (ANAB)
Simulations Plus Common Stocks (SLP)
Guardant Health Common Stocks (GH)

View all positions for First Light Asset Management

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
BlackRock
Polar Capital Holdings
Commodore Capital
Vestal Point Capital
Vanguard Group
Citadel Advisors
Fairmount Funds Management
VR Adviser
Novo A/S
Geode Capital Management
State Street Corporation
Logos Global Management
Pictet Asset Management Holding SA

View all funds holding Enliven Therapeutics